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OBJECTIVE
Diabetes damages major organ systems through disrupted glycemic control and
increased inflammation. The effects of diabetes on the lung have been of interest
for decades, but the modest reduction in pulmonary function and its nonpro-
gressive nature have limited its investigation. A recent systematic review found
that diabetes was associated with reductions in forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), and diffusing capacity for carbon monoxide of
the lung and increased FEV1/FVC. They reported pooled results including few
smokers. This study will examine measures of pulmonary function in participants
with extensive smoking exposure.
RESEARCH DESIGN AND METHODS
We examined pulmonary function in participants with a >10–pack-year history of
smoking with and without diabetes with and without chronic obstructive pul-
monary disease (COPD).Wemeasured pulmonary function, exercise capacity, and
pulmonary-related quality of life in 10,129 participants in the Genetic Epidemi-
ology of Chronic Obstructive Pulmonary Disease (COPDGene) Study.
RESULTS
Participants with diabetes were observed to have reduced pulmonary function
after controlling for known risk factors and also significant reductions in exercise
capacity and quality of life across functional stages of COPD.
CONCLUSIONS
Pulmonary function in patients with ‡10 pack-years of smoking and diabetes is
reduced, and this decrease is associated with significant reductions in activity-
related quality of life and exercise capacity.
Diabetes Care 2014;37:389–395 | DOI: 10.2337/dc13-1435
Reduced pulmonary function has been observed in patients with both type 1 and
type 2 diabetes (1–4). This functional impairment has been shown primarily through
cross-sectional associations between diabetes status and pulmonary function
measures, including the forced vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), and their ratio. van den Borst et al. (5) recently conducted a systematic
review and meta-analysis investigating pulmonary function in diabetes, which
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supports observations of a modest
reduction in FEV1, FVC, and diffusing
capacity for carbon monoxide of the
lung associated with both type 1 and
type 2 diabetes. This reduced lung
function manifests as a reduction in
FEV1% predicted of 2.8% in type 1
diabetes and 4.9% in type 2 diabetes
and a reduction of FVC% predicted of
3.8% in type 1 diabetes and 6.7% in type
2 diabetes. These reductions have not
been examined in patients with
extensive smoking exposure or a
diagnosis of chronic obstructive
pulmonary disease (COPD) (6,7).
Diabetes has not been shown to be a
strong predictor of pulmonary function
decline over time (8–10), suggesting
that pulmonary complications of
diabetes are not progressive, as is the
case with other complications of
diabeteswithmicrovascular origins such
as retinopathy, nephropathy, and
peripheral neuropathy. Reversal of
diabetes through simultaneous
pancreas and kidney transplantation has
been shown to ameliorate FEV1 and FVC
reductions in a select population (7).
The origins of pulmonary function
impairment in diabetes are thought to
derive from four primary sources:
nonenzymatic glycosylation of lung
collagen and elastin by advanced
glycosylation end products (AGEs)
generated by disrupted glycemic control
resulting in reduced elasticity of the lung
(1,11). Of potentially equal importance,
thickened alveolar epithelial basal
lamina and microvascular changes in
pulmonary capillary beds resulting in
reduced pulmonary capillary blood
volume and reduced diffusing capacity
have been reported (1,3,12). Autonomic
neuropathy affecting the phrenic
nerves, resulting in reducedmuscle tone
and control of the diaphragm, has been
observed (13,14). Finally, hyperglycemia
resulting in increased glucose in airway
surface liquid (ASL) serving as fuel for
bacteria and a subsequent increase in
the frequency of bacterial pathogens
isolated in the sputum. Increased
bacterial colonization has been shown
to lead to more frequent acute
exacerbations of COPD (AECOPD) and
worse outcomes from those
exacerbations (15–17). Each of these
pathways may work synergistically with
other pulmonary disorders, such as
COPD, potentially resulting in negative
outcomes for patients with both
disorders.
To the authors’ knowledge, there are no
reports of pulmonary function
reduction in patients with diabetes and
overt COPD. Given the importance of
smoking in COPD development, we
sought to investigate whether diabetes
was associated with pulmonary function
reduction in three groups of smokers:
the first is a population at risk for COPD
(.45 years of age and .10 pack-years
of smoking history with
postbronchodilator FEV1/FVC $0.70
and FEV1 .80%, control subjects), the
second is a group with frank COPD
(FEV1/FVC ,0.70 and FEV1 ,80%)
staged by the Global initiative for
chronic Obstructive Lung Disease
(GOLD) (COPD subjects), and a third
group with lung function impairment
characterized by reduced FEV1 and
preserved FEV1/FVC ratio (unclassified
spirometric abnormality subjects)
(Fig. 1). We investigated whether
diabetes, type 1 or 2, was associated
with reduced pulmonary function in
each of these groups, separating the
frank COPD group by spirometric GOLD
classification for severity. We also
investigated whether these groups
differed in functional capacity and
quality of life.
RESEARCH DESIGN AND METHODS
The Genetic Epidemiology of Chronic
Obstructive Pulmonary Disease
(COPDGene) Study is a large,
observational study designed to identify
genetic risk factors for COPD in a biracial
population of non-Hispanic white
(NHW) (approximately two-thirds) and
African American (approximately one-
third) smokers with at least a 10–pack-
year history of cigarette use. COPDGene
participants are between 45 and 80
years of age, span COPD disease
severity, and include both sexes from 21
study clinical centers (18). This study
presents results from the baseline visit
completed by 10,129 participants.
COPDGene conducted an extensive
study visit for each participant,
collecting demographic data, measures
of pulmonary function before and after
inhaled bronchodilator, health-related
quality of life, and chest CT.
Demographic data were collected
using a modified American Thoracic
Society (ATS) Respiratory Epidemiology
Questionnaire. Diabetes status was
determined using the question, “Has a
doctor ever told you that you have
diabetes?” or diabetes-specific
medication use was determined with an
open-ended question, “List all
medications, including those for your
lungs, you take that have been
prescribed by your health care provider
Figure 1—The prevalence of diabetes (type 1 or type 2) by GOLD classification.
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(physician, nurse practitioner, physician
assistant).” This open-ended question
was queried for any drugs specific to
diabetes by drug name and class.
Common misspellings were considered
where observed. All drugs in the
biguanide, thiazolidinedione,
sulfonylurea, meglitinide, a-glucosidase
inhibitor, incretin mimetic, DPP-4
inhibitor, amylin analogue, and insulin
families were identified, and if a patient
did not report diabetes but did report
one of these drugs, they were classified
as having diabetes. Type 1 and 2
diabetes were combined for these
analyses given the similarity in
pulmonary function reduction reported
in the literature. The age structure of
the COPDGene population and
medication use pattern suggest that the
majority of diabetes in this population is
likely type 2 diabetes.
Spirometry was measured using the ndd
EasyOne Spirometer, and all tests were
performed according guidelines
published by the ATS (19). A successful
session included three acceptable
maneuvers where the two best
measures for FEV1 and FVC were within
150 mL of each other. Based on a
standardized review process,
spirometry studies that did not meet
these criteria were selected for inclusion
or exclusion. Other assessments
included a measure of quality of
lifedthe St. George’s Respiratory
Questionnaire (SGRQ). Overall and
subscores were calculated using the
appropriate standard protocol (20).
Dyspnea was measured using the
Modified Medical Research Council
Dyspnea Scale (MMRC) using the
standard scoring protocol. Exercise
capacity was assessed using the
maximum distance a study subject could
walk on an unobstructed, flat, indoor
course in 6 min. Subjects were
supervised by a trained researcher
according to ATS guidelines (21).
Statistical analyses were performed
using the SAS system, version 9.3 (2002–
2008 by SAS Institute Inc., Cary, NC).
Univariate comparisons were performed
in normally distributed variables using a
Student t test, nonnormally distributed
variables were compared using Kruskal-
Wallis test, and categorical variables
were compared using x2. Multivariable
comparisons were performed using Proc
GLIMMIX least squaresmeans controlled
for the random effect of study center,
and all P values were two sided, with P,
0.05 considered significant. Multivariate
models of pulmonary function, quality of
life, and 6-min walk distance across
COPD GOLD stages were conducted
using the method above, controlling for
age, sex, current smoking status, pack-
years of smoking, ethnicity, and BMI, and
the levels of each measure were obtained
using least squares means. Multivariate
models using FEV1% predicted and FVC%
predicted did not include sex and ethnicity
as these covariates were accounted for in
the sex- and race-specific prediction
equations (22).
RESULTS
Thisanalysis reports on 10,129
participants recruited by the COPDGene
Study with GOLD stage 1, 2, 3, or 4 (n =
4,484; 13% with diabetes), smoking
controls without COPD (n = 4,388; 12%
with diabetes), and unclassified
spirometric abnormalities (GOLD
undefined) (n = 1,257; 22% with
diabetes). Fifty-four participants
without physician diagnosis of diabetes
were classified as having diabetes using
their medications alone, and 80% (n =
43) reported use of biguanides alone
(metformin or glucophage) and none
reported using insulin. In the
participants reporting physician
diagnosis of diabetes, 41% reported no
medication use and 71% reported
treatment with a single drug. Of those
reporting single drug use, 63% (n = 329)
reported use of a biguanide alone and
17% reported insulin alone.
As expected, those having diabetes
were older, were more likely to be male,
had a greater average BMI, had a greater
report of breathlessness (higher
dyspnea score), and were more likely to
have serious pulmonary exacerbations
(AECOPD) and pulmonary exacerbations
more frequently if they had COPD or
were GOLD undefined (Table 1). Among
COPD case subjects and smoking control
subjects, African Americans had a
greater prevalence of diabetes than
NHW (16 vs. 12%, P = 0.001, and 13 vs.
11%, P = 0.002). Thosewith diabetes had
greater pack-years of smoking history
Table 1—Demographic measures
Control subjects GOLD undefined COPD (GOLD 1, 2, 3, 4)
Diabetes No diabetes P Diabetes No diabetes P Diabetes No diabetes P
n 523 3,865 NA 282 975 NA 576 3,908 NA
Age (years 6 SD) 58.8 6 8.4 56.4 6 8.3 ,0.0001 58.8 6 7.7 56.8 6 8.3 0.0003 64.7 6 8.1 62.9 6 8.7 ,0.0001
Sex (% male) 57.0 52.3 0.045 52.1 44.4 0.02 62.5 55.0 0.0007
Ethnicity (% NHW) 54.1 59.5 0.02 57.1 56 0.7 72.2 78.1 0.002
Pack-years (years 6 SD) 40.7 6 22.8 36.7 6 19.8 0.0002 49.0 6 28.0 40.8 6 22.7 ,0.0001 58.5 6 33.7 50.6 6 26.0 ,0.0001
BMI (years 6 SD) 31.7 6 6.2 28.5 6 5.6 ,0.0001 35.4 6 7.2 30.7 6 7.0 ,0.0001 31.4 6 6.5 27.4 6 5.9 ,0.0001
MMRC dyspnea scale
(median, range) 0 (4) 0 (4) ,0.0001 2 (4) 1 (4) ,0.0001 3 (4) 2 (4) ,0.0001
AECOPD (% AECOPD+) 16.0 9.7 0.004 6.1 4.1 0.03 24.1 18.9 0.003
Exacerbation frequency
(median, range) 0 (6) 0 (6) 0.09 0 (6) 0 (6) 0.001 0 (6) 0 (6) ,0.0001
Comparisons of normally distributed variables were performed using Student t test and reported as mean 6 SD. Categorical variables were
compared using x2 and reported as percentages. Scales and counts were compared using Kruskal-Wallis one-way ANOVA and reported as median
and range. NA, not applicable.
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(59 vs. 51%, P , 0.0001 in COPD
subjects; 41 vs. 37%, P = 0.0002 in
control subjects; and 49 vs. 41%, P ,
0.0001 in GOLD-undefined subjects).
Among smokers without obstructive
disease, FEV1%, FVC, and FVC% were
significantly lower in those with
diabetes (Table 2), and this was also true
for spirometric measures in GOLD-
undefined individuals. Among COPD
case subjects (GOLD 1–4), FEV1 (in liters)
was not different by diabetes status
overall (20.02 L [95% CI 20.05 to
0.006], P = 0.1) or in individual
comparisons within GOLD stages. FVC
was significantly lower in participants
with diabetes overall (20.10 L [20.14 to
20.05], P , 0.0001) and was
significantly decreased in GOLD-
undefined, smoking control, and GOLD 2
subjects. Both FEV1% and FVC% were
significantly decreased overall in
participants with diabetes (20.8% [95%
CI21.5 to20.06], P = 0.03, and22.8%
[23.7 to 21.9], P , 0.0001). Smoking
control and GOLD-unclassified subjects
showed reduction in FEV1% and FVC%;
however, FEV1% was not reduced in
COPD. FVC% was reduced in GOLD
stages 2 and 3 but not stage 4. FEV1/FVC
ratio was increased in those with
diabetes overall (0.13 [95% CI 0.009–
0.02], P , 0.0001); statistically
significant increases in FEV1/FVC ratio
were observed among GOLD 2 and 3
subjects but not among other COPD
groups.
Exercise capacity, as measured by 6-min
walk distance, was significantly reduced
(290.2 feet [95% CI 2115.3 to 265.1],
P, 0.0001) in individuals with diabetes
across all lung function categories. Walk
distance reduction ranged between 45.6
and 129.3 feet and was consistently
decreased in participants with diabetes
(Fig. 2). Quality of life as measured by
SGRQ, a pulmonary-specific
questionnaire, was significantly worse
(higher score) in those with diabetes
overall (3.3 points [95% CI 2.0–4.7],
P, 0.0001) and among those participants
with diabetes, without COPD, GOLD
undefined, and GOLD 2–3 but not among
those with GOLD 1 or 4.
CONCLUSIONS
In the COPDGene population, we found
that diabetes is associated with
T
ab
le
2
—
P
u
lm
o
n
a
ry
fu
n
ct
io
n
a
n
d
o
u
tc
o
m
e
m
e
as
u
re
s
C
o
n
tr
o
ls
u
b
je
ct
s
G
O
LD
u
n
d
efi
n
ed
G
O
LD
1
G
O
LD
2
G
O
LD
3
G
O
LD
4
D
ia
b
et
es
N
o
d
ia
b
et
es
D
ia
b
et
es
N
o
d
ia
b
et
es
D
ia
b
et
es
N
o
d
ia
b
et
es
D
ia
b
et
es
N
o
d
ia
b
et
es
D
ia
b
et
es
N
o
d
ia
b
et
es
D
ia
b
et
es
N
o
d
ia
b
et
es
Pu
lm
o
n
ar
y
fu
n
ct
io
n
FE
V
1
(L
)
2.
71
**
*
2.
76
1.
9
4*
**
2.
0
3
2.
53
2.
5
4
1.
8
1
1.
8
4
1.
1
5
1.
1
0
0.
5
7
0.
57
FE
V
1
%
p
re
d
ic
te
d
95
.1
**
**
97
.0
67
.9
**
*
70
.5
89
.6
90
.0
63
.6
*
64
.9
41
.3
40
.0
22
.5
22
.5
FV
C
(L
)
3.
42
**
*
3.
50
2.
5
7*
**
2.
7
0
3.
83
3.
9
0
3.
0
0*
**
*
3.
1
6
2.
4
9
2.
5
7
1.
9
0
1.
92
FV
C
%
p
re
d
ic
te
d
93
.5
**
**
95
.8
69
.6
**
*
72
.3
10
3
.5
10
6
.1
81
.9
**
**
86
.0
68
.3
70
.9
51
.9
54
.6
FE
V
/F
V
C
0.
7
9
0.
78
0.
7
6
0.
7
6
0.
67
0.
6
6
0.
6
0*
**
0.
5
9
0.
4
8*
**
*
0.
4
5
0.
3
5
0.
33
St
u
d
y
o
u
tc
o
m
es
SG
R
Q
to
ta
ls
co
re
21
.5
**
**
18
.2
34
.2
**
**
26
.0
22
.7
22
.3
38
.5
**
**
33
.5
49
.1
*
46
.1
57
.2
57
.3
6-
m
in
w
al
k
d
is
ta
n
ce
(f
ee
t)
1,
32
5*
**
*
1,
39
7
1,
18
2*
**
*
1,
28
9
1,
31
0*
1,
39
8
1,
21
2*
1,
26
6
98
7
**
1,
08
1
63
6
**
76
2
V
al
u
es
ar
e
le
as
t
sq
u
ar
es
m
ea
n
s
o
f
ea
ch
m
ea
su
re
o
f
p
u
lm
o
n
ar
y
fu
n
ct
io
n
o
r
st
u
d
y
o
u
tc
o
m
e
ad
ju
st
ed
fo
r
st
u
d
y
si
te
,a
ge
,
se
x,
sm
o
ki
n
g
st
at
u
s,
p
ac
k-
ye
ar
s
o
f
sm
o
ki
n
g,
B
M
I,
d
ia
b
et
es
,G
O
LD
st
ag
e,
an
d
th
e
in
te
ra
ct
io
n
b
et
w
ee
n
d
ia
b
et
es
an
d
G
O
LD
st
ag
e.
*P
,
0.
0
5;
**
P
,
0.
0
1;
**
*P
,
0.
0
01
;
**
**
P
,
0.
0
00
1.
392 Pulmonary Function in Smokers With Diabetes Diabetes Care Volume 37, February 2014
decreased lung function in current and
former smokers with a .10–pack-year
history of smoking who do not have
obstructive lung disease. Themagnitude
of the differences we observed was
small but in keeping with previous
studies of pulmonary function
conducted primarily in populations with
less overall smoking exposure. This
decrease in function is manifest in all
Pulmonary Function Test (PFT)-based
measures in our study, with the
exception of FEV1.These participants
also exhibit reduced 6-min walk
distance and worse quality of life.
Participants with COPD also show
reduced pulmonary function by several
measures, including reduced 6-min walk
distance. GOLD-unclassified participants
show the most consistent effect of
diabetes, with all measures showing
reduction. As COPD severity worsened,
there were fewer differences in
pulmonary function measures related to
diabetes, with GOLD 2 showing
significantly lower pulmonary function
among three PFT parameters (FVC, FVC%
predicted, and FEV1/FVC ratio) (Table 2).
Among GOLD 3 individuals, there were
two functional parameters that were
significantly reduced in diabetes (FVC%
predicted and FEV1/FVC). In GOLD 4
individuals, none of the functional
measures were significantly lower in
diabetes. The overall picture of the effect
of diabetes on pulmonary function is of
small reductions exhibiting important
effects on functional capacity and quality
of life. The pattern observed in these
participants is restrictive, e.g., lower FVC
and higher FEV1/FVC, which is consistent
with potential biological mechanisms,
such as collagen cross-linking in the lung
associated with glycemic dysregulation
and AGE exposure.
A meta-analysis conducted by van den
Borst et al. (5) demonstrated a pooled
estimate of reduction in FEV1% of
5.07%, reduction in FVC% of 6.31%, and
increase in FEV1/FVC of 0.12. This study
included limited numbers of current
smokers and lacked data regarding
former smoke exposure. Our study
explores a population exposed to
substantial cumulative smoke exposure
($10 pack-years) and reports smaller
but comparable reductions in former
smokers, reduction in FEV1% of 1.90%,
reduction in FVC% of 2.30%, and
increase in FEV1/FVC of 0.01. In
participants with COPD, FEV1%
reduction was lower than in smoking
control subjects and reduction in FVC%
was higher than in smoking control
subjects but did not reach the difference
observed in the meta-analysis (Table 2).
GOLD-unclassified subjects also showed
similar levels of reduction that did not
reach the levels observed in that study.
The magnitude of the differences
observed that is attributable to diabetes
might be expected to be reduced given
the large effect of smoking. This is also
true of the COPD lung where the
restrictive effect of diabetes might be
hypothesized to be masked by smoking
and obstructive disease. Our
observation of significant functional
reduction, worse quality of life, and
6-min walk distance in participants with
COPD underscores the importance of
diabetes on the pulmonary system,
which may not be appreciated using
spirometry alone.
Figure 2—The results of the 6-min walk test in feet by GOLD classification and diabetes status. Levels are least squares means adjusted for study site,
age, sex, smoking status, pack-years of smoking, BMI, diabetes, GOLD stage, and the interaction between diabetes and GOLD stage. *P, 0.05; **P,
0.01; ***P , 0.0001.
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The COPDGene Study differs in
important ways from the studies used in
the systematic review and meta-
analysis, primarily in that it represents
heavy smoking exposure and measures
diabetes in a less than optimal fashion.
The study design allows us to
compensate somewhat for an imprecise
measurement of diabetes in that self-
report of diabetes in 10,129 participants
is highly unlikely to be biased to such an
extent that it influences the outcome,
and incorrect report of diabetes
diagnosis would bias our results in a
conservative direction. Participants with
undiagnosed and untreated diabetes
would likely have worse glycemic
control than participants who were
treated, and this would likely also
generate bias in a conservative
direction. Our observation of
medication use in participants reporting
diabetes is comparable to that reported
by the Centers for Disease Control and
Prevention (23). The size of the study
also allows a very precise measure of
pulmonary function, and the emphasis
of COPDGene on pulmonary outcomes
ensures that the outcome was
measured consistently. The data
reported are cross-sectional and likely
include a survival bias and are subject to
the weaknesses inherent in that type of
study design.
Patients with diabetes receiving
simultaneous pancreas and kidney
transplantation showed significantly
improved pulmonary function
measured by FEV1 but not measured by
FVC or total lung capacity (7). This
suggests that the elimination of
diabetes improved pulmonary function
without directly affecting lung
structure, implying an effect of the
diabetic milieu on pulmonary function
irrespective of the pulmonary damage
associated with smoking. Diabetes
represents a disruption in glycemic
control and increased exposure to AGEs.
The receptor for AGEs (RAGE) has been
shown to localize to the basal cell
membrane of alveolar type 1 epithelial
cells (24). Genetic studies confirm an
association between polymorphisms in
the AGER gene and reductions in
pulmonary function without
considering the effect of diabetes (25).
This suggests that altered function of
RAGE may play an important role in the
restrictive lung disease observed in
diabetes. A reduction in exercise
capacity has been observed in patients
with diabetes, and this reduction has
been shown to be associated with
microvascular blood flow defects at the
muscle (26) as well as cardiac
dysfunction (27). This reduction in
capillary blood volume has also been
observed in studies of gas transfer in
people with diabetes (28). Diabetes is
the leading cause of neuropathies in
humans, and one target is the phrenic
nerve. Diabetic phrenic neuropathy has
been shown to present as respiratory
weakness (14) or failure (29) and to
occur before the onset of frank diabetes
(13). Whereas this study is not able to
assess phrenic neuropathy, future
studies should consider
subsymptomatic phrenic dysfunction
related to diabetes. This study also
shows significant dyspnea and AECOPD
and a higher frequency of pulmonary
exacerbations related to diabetes,
suggesting that diabetes is directly
related to serious lung problems beyond
those discussed above. Lastly, 6-min
walk distancemeasures both pulmonary
and extrapulmonary manifestations of
COPD. Spruit et al. (30) showed that
patients that were unable to exceed
1,095 feet in walk distance were at
increased risk of death, and an
individual experiencing a reduction in
walk distance of 98.4 feet has been
shown to be at increased risk for death
(31). Our study shows a decrease in walk
distance in participants with diabetes
overall of 90.2 feet (95% CI 115.3–65.1,
P , 0.0001). The magnitude of this
decreased functional capacity suggests
serious increased risk of death for
participants with diabetes and COPD.
Annual assessment of 6-min walk
distance in patients with diabetes may
represent an important and cost-
effective addition to commonly
measured clinical markers.
Pulmonary function in patients with
$10 pack-years of smoking and
diabetes is reduced, and this decrease is
associated with significant reductions in
activity-related quality of life and
exercise capacity. This reduction is
evident in those with and without COPD
and in participants without defined
obstructive lung disease. Additional
work is needed to understand the
influence of the biological pathways
linking diabetes and reduced pulmonary
function in order to identify appropriate
treatments that consider both diabetes
and COPD.
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